Valur Ragnarsson has been appointed as Chairman of the Board by Coripharma’s Board of Directors.
Valur is a pharmaceutical executive with a solid track record spanning over 30 years, driving financial results and sustainable growth in the global generic pharmaceutical industry, describes the company.
Valur has been a part of Coripharma’s Board of Directors since April 2020. Previously he served as the global CEO of Medis, a subsidiary of Teva Pharmaceuticals. During his tenure, he led the transformation of Medis from a relatively small player within the business-to-business pharma sector to a leading company in its field. His earlier positions include Executive Vice President, Third PartySales, at Actavis Group as well as roles within Aventis (later Sanofi Aventis) and Lundbeck. He has served on the board of several pharmaceutical companies.
Valur has an M.Sc. Pharmacy degree from the University of Iceland.
Photo of Valur Ragnarsson: Coripharma